Get started
Author

Giuseppe Colantuoni

Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma
2000 · Francesco Perrone, Bruno Daniele, et al. · Hepatology · 520
PDF
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
2015 · Lucia Del Mastro, Sabino De Placido, et al. · The Lancet · 206
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
2007 · Cesare Gridelli, Paolo Maione, et al. · The Oncologist · 119
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
2006 · F Ciardiello, T Troiani, et al. · British Journal of Cancer · 83
PDF
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
2014 · F. Perrone, F. Nuzzo, et al. · Annals of Oncology · 70
PDF
Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer
2009 · Cesare Gridelli, Antonio Rossi, et al. · The Oncologist · 65
PDF
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
2022 · Lucia Del Mastro, Francesca Poggio, et al. · The Lancet Oncology · 55
Etoposideversus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: Results of a prospective randomized fonicap trial
1990 · Riccardo Rosso, Franco Salvati, et al. · Cancer · 52
Treatment of Small Cell Lung Cancer in the Elderly
2005 · Antonio Rossi, Paolo Maione, et al. · The Oncologist · 48
PDF
A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cance
2004 · F. Ciardiello, T. Troiani, et al. · Journal of Clinical Oncology · 42
Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.
2003 · Antonio Rossi, Cesare Gridelli, et al. · PubMed · 34
Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
2009 · Antonio Rossi, Paolo Maione, et al. · Current Drug Discovery Technologies · 32
The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
2011 · M. A. Bareschino, C. Schettino, et al. · Current Medicinal Chemistry · 31
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
2012 · F. Nuzzo, C. Gallo, et al. · Annals of Oncology · 30
PDF
Screening for lung cancer: New horizons?
2005 · Antonio Rossi, Paolo Maione, et al. · Critical Reviews in Oncology/Hematology · 26
Chemotherapy of advanced NSCLC in special patient population
2006 · C. Gridelli, P. Maione, et al. · Annals of Oncology · 20
PDF
The role of new targeted therapies in small-cell lung cancer
2004 · A Rossi, P Maione, et al. · Critical Reviews in Oncology/Hematology · 20
Weekly Low Dose Epirubicin in Elderly Cancer Patients
1996 · Dario Nicolella, Giuseppe Grimaldi, et al. · Tumori Journal · 19
Management of unfit older patients with advanced NSCLC
2009 · Cesare Gridelli, Paolo Maione, et al. · Cancer Treatment Reviews · 17
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
2018 · Ferdinando Riccardi, Giuseppe Colantuoni, et al. · Molecular and Clinical Oncology · 15
PDF
Erlotinib in non-small-cell lung cancer
2007 · Cesare Gridelli, Antonio Rossi, et al. · Expert Opinion on Pharmacotherapy · 13
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
2020 · Salvatore Del Prete, Liliana Montella, et al. · Oncotarget · 12
PDF
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
2021 · Fabio Puglisi, Lorenzo Gerratana, et al. · npj Breast Cancer · 11
PDF
Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study
2013 · F Cognetti, P Bruzzi, et al. · Cancer Research · 11
New avenues for second-line treatment of metastatic non-small-cell lung cancer
2008 · Cesare Gridelli, Paolo Maione, et al. · Expert Review of Anticancer Therapy · 11
Works count: 47
Citation count: 1,597
H-index: 18
I10-index: 25
Year
Topic
Type